Supervisory Board

Successful decision-makers from a broad range of industries.

Dr. Hubert Birner

Chairman of the Board

Dr. Birner is responsible for TVM Capital Life Science’s overall investment strategy and fund operations in North America and Europe. He also serves as a member of the fund advisory board of TVM Capital Life Science’s China BioPharma Capital I fund. Dr. Birner joined TVM Capital in 2000 as an investment manager Prior his tenure at TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development. Before starting his professional career in business, he earned substantial academic merits, including a  position as Assistant Professor for biochemistry at the Ludwig-Maximilian-University (LMU). Dr. Birner additionally holds an MBA from Harvard Business School.

Dr. Theron E. Odlaug

Member of the Board

Dr. Odlaug’s over 35 years of experience includes senior leadership roles with Astellas, Fujisawa, Bayer AG and Baxter. He is CEO of Impopharma Inc, till 12/2016 he was CEO of leon-nanodrugs GmbH and leon-nanodrugs Inc. Prevously he was Executive Chairman of Cedarburg Pharmaceuticals Inc., Executive Chairman and CEO of Planet Biopharmaceuticals, Inc., President and Chief Executive Officer of CyDex Pharmaceuticals Inc. and Managing Partner of EIR Healthcare Advisors LLC.


Cornelia Beier

Member of the Board

Cornelia Beier is a co-founder of leon-nanodrugs and was the managing director over 5 years. She has 30 years of experiences in the pharmaceutical and biotech industries (BMS, Takeda, Pharmacia etc.) and is focused on business development strategies, marketing, consulting, human resources and controlling in life sciences and healthcare. She was a co-founder of Oncology World, Munich, and Partner and CEO of Kohtes Klewes Healthcare (today Ketchum PLEON-Group – BBDO), Munich and Düsseldorf.

Daniel Parera

Member of the Board

Daniel joined the TVM Capital Life Science team as Executive-in-Residence based in Munich in September 2016, where he is responsible for deal sourcing, deal monitoring as well as transaction advisory. Next to leon-nanodrugs GmbH, he serves as a member of the Board of Directors at Centogene AG, Rostock, MicrobeDx, Inc. Los Angeles, CA and Mediti Pharma, Inc. Montreal, QC (Observer). Daniel spent 12 years at Novartis in three Divisions including Pharma in Basel, Switzerland, Vaccines & Diagnostics in Emeryville, CA, USA and Sandoz (Generics / Biopharmaceuticals) in Holzkirchen / Munich, Germany, holding various line function roles in Marketing, Development, BD&L and Strategy. He is an MD from Johannes-Gutenberg-University Mainz, Germany with clinical training in Germany, Switzerland and the USA

James C. Gale

Member of the Board

James Gale is the founding partner of Signet Healthcare Partners. He initiates investments and provides active management oversight to a number of the portfolio companies. He is currently the Chairman of the Board of Alpex Pharma S.A. and IGI Labs,Inc., and also serves on the Board of Directors of Bionpharma Inc., Chr. Olesen Synthesis A/S, CoreRx Inc, and Spepharm AG, Mr. Gale received his Masters of Business Administration from the University of Chicago.

Dr. Frank Mathias

Dr. Frank Mathias is Chief Executive Officer of Rentschler Biotechnologie GmbH since January 2016. Frank Mathias, previously (May 2009 to January 2016) CEO of Medigene AG, possesses over 25 years of relevant experience in the pharmaceutical and biotech industries. He holds a PhD in pharmacy in the field of immunology and worked for Hoechst, among other companies, prior to assuming the General Manager position at Servier Deutschland GmbH in Munich. In 2002, he joined Amgen GmbH, Munich, as Head of Marketing. Where he served as the company’s General Manager from 2003 – 2008.

Dr. Gerhard Ries

Dr. Gerhard Ries is Managing Partner of LifeCare Partners, a dedicated VC/PE firm in the European healthcare sector. Mr. Ries has more than 20 years of global pharma industry and VC experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, and Roche (Boehringer Mannheim). Mr. Ries was Founder and Managing Partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies, including 4-Antibody, Activaero, Affimed, Curetis, Delenex, Develco Pharma, Esbatech, Eyesense, Glycart, Lipomed, Vaximm, etc. Mr. Ries holds a M.S. and Ph.D. degree in Molecular Biology from the University of Basel and a M.S. degree in Biotechnology from the Fachhochschule Weihenstephan (Munich).

Peter Thornton

Peter Thornton is CFO of Technopath Clinical Diagnostics. He has extensive experience in pharmaceuticals and drug delivery as a senior executive at Alkermes plc, Elan Corporation plc and Agenus Inc. He has served as a director of both public and private companies including Merrion Pharmaceuticals plc and Cydex Pharmaceuticals Inc. and is currently a director of Valitacell Limited and leon-nanodrugs GmbH. Peter is a KPMG qualified Chartered Accountant and holds a BComm degree from University College Cork, Ireland.

By closing this message, you consent to our cookies on this device in accordance with our cookie policy. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our privacy policy.

Read more